Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Asset disposition
Quarterly results
Director departure
INFINITY PHARMACEUTICALS, INC. (INFI) Create: Alert

All | News | Filings
Date FiledTypeDescription
09/29/2023 8-K Bankruptcy or Receivership, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officer...
08/10/2023 10-Q Quarterly Report for the period ended June 30, 2023
07/25/2023 8-K Quarterly results
07/24/2023 8-K Quarterly results
07/14/2023 8-K Quarterly results
07/10/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
07/05/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
07/03/2023 425 Form 425 - Prospectuses and communications, business combinations:
07/03/2023 8-K Quarterly results
07/03/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
06/30/2023 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing  Interact...
06/29/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
06/16/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
06/16/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
06/06/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
06/06/2023 DEFM14A Form DEFM14A - Definitive proxy statement relating to merger or acquisition:
05/09/2023 10-Q Quarterly Report for the period ended March 31, 2023
03/28/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
03/28/2023 425 Form 425 - Prospectuses and communications, business combinations:
03/28/2023 8-K Quarterly results
03/28/2023 10-K Annual Report for the period ended December 31, 2022
02/23/2023 425 Form 425 - Prospectuses and communications, business combinations:
02/23/2023 425 Form 425 - Prospectuses and communications, business combinations:
02/23/2023 8-K Acquisition/merger/asset purchase announced
02/09/2023 SC 13G/A VANGUARD GROUP INC reports a 6% stake in Infinity Pharmaceuticals Inc.
12/30/2022 8-K Quarterly results
11/14/2022 8-K Quarterly results
Docs: "Infinity Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update – MARIO-3 Update in Patients with 1L TNBC showing 52% increase in one-year progression free survival rate in ITT patient population compared to Impassion130 benchmark –"
11/14/2022 10-Q Quarterly Report for the period ended September 30, 2022
08/25/2022 8-K Other Events  Interactive Data
08/09/2022 8-K Quarterly results
Docs: "Infinity Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update – Positive eganelisib data from two-year landmark analysis demonstrate durable survival benefit in urothelial cancer patients from MARIO-275 –"
08/09/2022 10-Q Quarterly Report for the period ended June 30, 2022
08/04/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
07/08/2022 SC 13G Form SC 13G - Statement of acquisition of beneficial ownership by individuals:
06/16/2022 4 EVNIN ANTHONY B (Director) has filed a Form 4 on INFINITY PHARMACEUTICALS, INC.
Txns: Granted 46,378 shares @ $0.679, valued at $31.5k
Granted 45,000 options to buy @ $0.679, valued at $30.6k
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy